EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse

Julia Mann, Kathrin Niedermayer, Johannes Krautstrunk, Lena Abbey, Lisa Wiesmüller, Roland P Piekorz, Gerhard Fritz iD

International Journal of Cancer · 15.01.2025 · 156 (2) · 389-402

DOI: 10.1002/ijc.35164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 06.09.2024. Verfasst von Julia Mann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Toxicology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Rad51 Recombinase, Cisplatin, Checkpoint Kinase 1, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic efficacy of the anticancer drug cisplatin is limited by acquired drug resistance. Cisplatin forms DNA crosslinks, that, if not removed, lead to replication stress. Due to this, the DNA damage response (DDR) gets activated regulating cell cycle arrest, DNA repair, cell death or survival. This makes DDR components promising targets for the development of new therapeutic approaches aiming to overcome acquired drug resistance. To this end, cisplatin‐resistant bladder cancer cells were analyzed regarding their sensitivity to combination treatments with selected pharmacological DDR inhibitors. Synergistic cytolethal effects were achieved after combined treatment with low to moderate doses of the non‐genotoxic RAD51‐inhibitor (RAD51 i ) B02 and CHK1‐inhibitor (CHK1 i ) PF477736. This effect was also found in cisplatin resistant tumor cells of other origin as well as with other RAD51 i and CHK1 i . Combined treatments promoted decelerated replication, S‐phase blockage, accumulation of DNA strand breaks, DDR activation and stimulation of apoptotic cell death as compared to mono‐treatment, which is independent of the expression of RAD51, CHK1, and PrimPol. Based on these data, we suggest combined inhibition of RAD51 and CHK1 to overcome acquired cisplatin resistance of malignant cells. We propose that the molecular mechanism of this synergistic toxicity relies on a simultaneous inactivation of two key DNA damage tolerance pathways regulating replication fork restart, thereby circumventing the activation of alternative compensatory mechanisms and, in consequence, eventually effectively triggering apoptotic cell death by replication fork collapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rad51 RecombinaseCisplatinCheckpoint Kinase 1Drug Resistance, NeoplasmDrug SynergismDNA ReplicationHumansCell Line, TumorUrinary Bladder NeoplasmsDNA DamageAntineoplastic AgentsApoptosisBenzodiazepinonesPyrazoles

Stichwörter der Autor:innen

DNA damageDNA repairbladder cancercisplatin resistancereplicative stress

Substanzen

Rad51 RecombinaseCisplatinCheckpoint Kinase 1CHEK1 protein, humanRAD51 protein, humanAntineoplastic AgentsPF 00477736BenzodiazepinonesPyrazoles

Autor:innen und Institutionen

  • Institute of Toxicology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Department of Obstetrics and Gynecology, Ulm University, Ulm, Germany.
  • Institute of Biochemistryand Molecular Biology II, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

ORCID-Profile: Gerhard Fritz

Förderung

  • Deutsche Forschungsgemeinschaft
  • Deutsche Krebshilfe

Zitieren

APA

Mann, J., Niedermayer, K., Krautstrunk, J., Abbey, L., Wiesmüller, L., Piekorz, R. P., & Fritz, G. (2025). Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse. International Journal of Cancer, 156(2), 389-402. https://doi.org/10.1002/ijc.35164

Vancouver

Mann J, Niedermayer K, Krautstrunk J, Abbey L, Wiesmüller L, Piekorz RP, et al. Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse. International Journal of Cancer. 2025;156(2):389-402. doi:10.1002/ijc.35164

BibTeX
@article{Mann2025,
  author = {Mann, Julia and Niedermayer, Kathrin and Krautstrunk, Johannes and Abbey, Lena and Wiesmüller, Lisa and Piekorz, Roland P and Fritz, Gerhard},
  title = {Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse},
  journal = {International Journal of Cancer},
  year = {2025},
  volume = {156},
  number = {2},
  pages = {389--402},
  doi = {10.1002/ijc.35164}
}
Kostenlos starten →